Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYTOIN vs BRIVARACETAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Generalized tonic-clonic seizures (grand mal epilepsy),Complex partial seizures (psychomotor/temporal lobe seizures),Prevention and treatment of seizures occurring during or following neurosurgery,Status epilepticus (intravenous formulation)
Adjunctive therapy in the treatment of partial-onset seizures (POS) in patients 4 years of age and older with epilepsy
Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
Average terminal half-life 22 hours (range 7–42 hours) in adults; dose-dependent due to saturation of metabolism at therapeutic concentrations (10–20 mg/L). Half-life increases with higher doses.
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (Cr Cl <30 m L/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Phenytoin is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, with minor contributions from CYP2C19. The major metabolite is the glucuronide conjugate of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin exhibits dose-dependent, saturable (Michaelis-Menten) pharmacokinetics.
Brivaracetam is primarily metabolized by hydrolysis of the acetamide group via amide bond hydrolysis (not cytochrome P450), forming the inactive carboxylic acid metabolite (M1). A minor pathway is hydroxylation via CYP2C19, producing the hydroxyl metabolite (M2).
Primarily hepatic metabolism (>95%); less than 5% excreted unchanged in urine. Renal excretion of metabolites (glucuronides) accounts for ~80% of elimination; biliary/fecal excretion of metabolites ~20%.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
90–95% bound, primarily to albumin; binding is saturable and decreases in hypoalbuminemia, uremia, or with other highly bound drugs.
Less than 20% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Binding is concentration-independent and low, minimizing displacement interactions.
0.6–0.8 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier; Vd increases in neonates and decreases in renal failure.
Volume of distribution is approximately 0.5 L/kg (range 0.3-0.6 L/kg), indicating distribution into total body water with moderate tissue binding.
Oral: 90–100% (phenytoin sodium extended-release); IM: low and erratic (not recommended) due to precipitation and slow absorption.
Oral bioavailability is approximately 90% (range 80-100%), with rapid absorption. Food does not significantly affect absorption. Absolute bioavailability is 100% for intravenous administration.
No specific GFR-based adjustment required; use with caution in severe renal impairment (GFR < 10 m L/min) due to protein binding changes.
Cr Cl ≥50 m L/min: no adjustment. Cr Cl 30-49 m L/min: 25-50 mg twice daily. Cr Cl 15-29 m L/min: 12.5-25 mg twice daily. Cr Cl <15 m L/min: 12.5-25 mg once daily. Hemodialysis: 12.5-25 mg once daily, with supplemental dose after dialysis.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 25-50%; Child-Pugh C: Reduce dose by 50-75%.
Child-Pugh A: no adjustment. Child-Pugh B: 12.5-25 mg twice daily, initial dose 12.5 mg twice daily. Child-Pugh C: not recommended.
Loading dose: 15-20 mg/kg IV/PO; Maintenance: 5-10 mg/kg/day PO in 2-3 divided doses.
Age ≥1 month to <16 years: weight-based dosing. Initially 1.25 mg/kg twice daily, maximum 2.5 mg/kg twice daily. Total daily dose range: 2.5-5 mg/kg/day. Maximum 200 mg/day.
Start at low end of dosing range (e.g., 3 mg/kg/day); monitor for toxicity; consider reduced protein binding and slower metabolism.
Initiate at lower dose (12.5-25 mg twice daily) due to decreased renal function; titrate slowly. Monitor renal function and neuropsychiatric effects.
Intravenous administration of phenytoin is associated with serious cardiovascular adverse reactions including severe hypotension and cardiac arrhythmias (e.g., bradycardia, heart block, ventricular fibrillation). These reactions can occur more frequently in patients with advanced age, known cardiac disease, or those receiving other medications that affect the cardiovascular system. Continuous monitoring of ECG and vital signs is required during IV administration, and the rate of infusion should not exceed 50 mg/min in adults.
None
Cardiovascular risk during IV administration (see black box warning),Hypersensitivity reactions: Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS),Hepatic injury: Acute hepatotoxicity, including elevated liver enzymes and hepatitis,Hematologic effects: Agranulocytosis, thrombocytopenia, leukopenia, pancytopenia,Central nervous system effects: Nystagmus, ataxia, slurred speech, mental confusion, dizziness, drowsiness,Hyperglycemia: May elevate blood glucose levels,Osteomalacia and hypocalcemia due to altered vitamin D metabolism,Teratogenicity: Fetal hydantoin syndrome (craniofacial abnormalities, growth deficiency, intellectual disability),Birth defects: Increased risk of cardiovascular malformations and neural tube defects,Carcinogenicity: Long-term use associated with increased risk of malignancies (lymphoma, hepatocellular carcinoma)
Suicidal ideation and behavior: Monitor for emergence or worsening of depression, suicidal thoughts/behavior, or unusual mood changes.,Neurological adverse reactions: Dizziness, somnolence, and coordination difficulties (ataxia, gait disturbance, vertigo).,Withdrawal: Abrupt discontinuation may precipitate withdrawal seizures; taper gradually.
Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation,Sinus bradycardia, sinoatrial block, second- or third-degree AV block, Adams-Stokes syndrome,Concurrent use with delavirdine (due to decreased delavirdine concentrations),History of prior acute hepatotoxicity attributable to phenytoin,Porphyria (may precipitate acute attacks)
Hypersensitivity to brivaracetam or any of its inactive ingredients
Enteral tube feedings can decrease phenytoin absorption; hold feeds 1-2 hours before and after administration. High-fat meals may increase absorption consistency. Folic acid supplementation may lower phenytoin levels. Calcium supplements and antacids can impair absorption; separate by 2-3 hours.
No significant food interactions. Alcohol may increase central nervous system depression; avoid or limit alcohol consumption.
Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during first trimester (organogenesis). Second and third trimester exposure may cause impaired fetal growth, microcephaly, and neurodevelopmental delay. Risk of major malformations is dose-dependent and increases with polytherapy.
First trimester: Limited human data; animal studies show increased fetal malformations (e.g., skeletal abnormalities) at clinically relevant doses. Second and third trimesters: Potential for neurodevelopmental effects; avoid use unless benefit outweighs risk. Overall: Considered possibly teratogenic (FDA Pregnancy Category C equivalent).
Phenytoin is excreted into breast milk with estimated infant dose of 2-10% of maternal weight-adjusted dose; M/P ratio approximately 0.18-0.45. Generally considered compatible with breastfeeding; monitor infant for drowsiness, poor feeding, and rash. Avoid if maternal dose >400 mg/day or signs of infant toxicity.
Brivaracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure estimated at 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and weight gain. Benefit of breastfeeding may outweigh risks with caution.
Pregnancy decreases phenytoin concentrations due to increased clearance (hepatic induction, increased Vd, decreased albumin). Dose adjustments are frequently required: increase total daily dose by 30-50% on average, guided by free phenytoin concentrations (target 1-2 mcg/m L). Monitor serum levels every 2-4 weeks, especially in third trimester. Postpartum, dose should be reduced to prepregnancy levels over 1-2 weeks to avoid toxicity.
Pregnancy can decrease brivaracetam concentrations by 30-40% due to increased clearance and volume of distribution. Monitor clinical response and consider therapeutic drug monitoring to maintain trough levels within non-pregnant target range (0.5-10 mcg/m L). May require dose increase of 50-100% in second and third trimesters. Postpartum: Reduce dose to pre-pregnancy levels over 1-2 weeks to avoid toxicity.
Phenytoin exhibits zero-order kinetics at therapeutic levels; small dose increases can cause toxicity. Monitor free phenytoin levels in hypoalbuminemia or uremia. Fosphenytoin is a prodrug used for IV loading with fewer infusion-site reactions. Caution in CYP2C9 poor metabolizers; consider genetic testing. May cause folate deficiency, peripheral neuropathy, and osteomalacia with long-term use. Co-administration with valproate displaces phenytoin from protein binding, increasing free fraction.
Brivaracetam is a SV2A ligand with higher affinity and selectivity than levetiracetam. It does not require dose adjustment in renal impairment unless creatinine clearance <30 m L/min. Do not use in patients with hepatic impairment. Onset of action is rapid; oral and IV formulations are bioequivalent. Monitor for psychiatric symptoms (e.g., aggression, psychosis) and somnolence. No need for titration; starting dose 50-100 mg/day divided twice daily.
Take exactly as prescribed; do not skip doses or change brands without consulting your doctor.,Do not stop taking suddenly as this may cause withdrawal seizures.,Avoid alcohol as it can affect drug levels and increase side effects.,Report any rash, fever, swollen glands, or mouth sores immediately (risk of Stevens-Johnson syndrome).,Use reliable contraception if sexually active; phenytoin reduces effectiveness of hormonal contraceptives.,Maintain good dental hygiene and see dentist regularly; may cause gum overgrowth.,Take with food if stomach upset occurs, but avoid high-fat meals if consistent timing is needed.,May cause dizziness, drowsiness, or blurred vision; avoid driving until you know how it affects you.
Take brivaracetam exactly as prescribed, with or without food.,Do not stop taking this medication suddenly, as it may increase seizure frequency.,Report any mood changes, aggression, or thoughts of self-harm immediately.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,If you have liver disease, inform your doctor before starting brivaracetam.,Store at room temperature, away from moisture and heat.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Phenytoin is a potent inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes. Dasatinib is primarily metabolized by CYP3A4. Coadministration with phenytoin significantly reduces dasatinib plasma concentrations, potentially leading to subtherapeutic levels, reduced efficacy, and increased risk of disease progression in chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia."
"Phenytoin, a known inducer of CYP450 enzymes (particularly CYP3A4 and CYP2C9), increases the hepatic metabolism of ambroxol, a mucolytic agent primarily metabolized via CYP3A4. This induction reduces ambroxol plasma concentrations, potentially diminishing its therapeutic efficacy in clearing respiratory secretions. Clinically, patients may experience reduced mucolytic effects, leading to inadequate clearance of bronchial secretions and worsening of underlying respiratory conditions."
"Mianserin, a tetracyclic antidepressant with strong antihistaminergic and alpha2-adrenergic antagonist properties, may reduce the anticonvulsant efficacy of brivaracetam. By blocking presynaptic alpha2-adrenoceptors, mianserin enhances norepinephrine release, which can modulate neuronal excitability and potentially counteract the synaptic vesicle protein 2A (SV2A) binding mechanism of brivaracetam. This pharmacodynamic opposition may lead to increased seizure frequency or breakthrough seizures in patients with epilepsy when coadministered."
"Pentobarbital, a potent enzyme-inducing barbiturate, significantly increases the hepatic metabolism of brivaracetam, a second-generation antiepileptic drug, via induction of CYP3A4 and other metabolic enzymes. This interaction leads to reduced plasma concentrations of brivaracetam, potentially diminishing its antiseizure efficacy and increasing the risk of breakthrough seizures. Clinically, patients may require dose adjustment of brivaracetam or alternative therapy to maintain therapeutic effect."
"Brivaracetam may inhibit the metabolism of diltiazem, a calcium channel blocker, primarily via competition for CYP3A4 enzyme, leading to increased plasma concentrations of diltiazem. This can potentiate its therapeutic and adverse effects, including bradycardia, hypotension, and atrioventricular block. Clinical outcomes may include enhanced antihypertensive efficacy or increased risk of heart block, particularly in patients with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYTOIN vs BRIVARACETAM, answered by our medical review team.
PHENYTOIN is a Anticonvulsant that works by Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.. BRIVARACETAM is a Anticonvulsant that works by Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYTOIN and BRIVARACETAM depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYTOIN is: Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.. The standard adult dose of BRIVARACETAM is: 50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PHENYTOIN and BRIVARACETAM. The metabolism of Brivaracetam can be increased when combined with Phenytoin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PHENYTOIN is classified as Category D/X. Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during f. BRIVARACETAM is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (e.g., skeletal abnormalities) at clinically relevant doses. Second and third trimesters: Pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.